3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Advanced Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a low-toxicity, high-affinity inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC50 of approximately 50 nM in CHO cells, enabling >95% PARP inhibition at concentrations above 1 μM [product]. It is soluble in water, ethanol, and DMSO under ultrasonic assistance, with optimal storage at -20°C. The compound ameliorates diabetes-induced nephropathy in db/db mouse models and enhances endothelial nitric oxide-mediated vasorelaxation following oxidative stress (contrast: advanced mechanistic roles). PARP inhibition by 3-Aminobenzamide is central to studies dissecting ADP-ribosylation biology and innate immunity, as evidenced by enhanced virus replication upon pan-PARP inhibition in primary macrophages (Grunewald et al., 2019). Research use only; not for diagnostic or medical applications.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are enzymes mediating ADP-ribosylation, a reversible post-translational modification that regulates DNA repair, cell death, and stress responses (Grunewald et al., 2019). Humans encode 17 PARPs, of which PARP1 and PARP2 are primary mediators of poly-ADP-ribosylation. PARP activity is critical for cellular responses to DNA damage and oxidative stress. Viral macrodomains counteract host PARP activity to evade innate immunity. Inhibiting PARP activity with small molecules like 3-Aminobenzamide (PARP-IN-1) enables precise study of these pathways and their relevance in disease models, such as diabetic nephropathy and viral pathogenesis. The compound's selectivity and potency make it a valuable reference agent for dissecting PARP-related processes in research applications (see: scientific depth, diabetic nephropathy).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide (PARP-IN-1) acts as a competitive inhibitor of the NAD⁺-binding site on PARP enzymes. By occupying this site, it prevents the transfer of ADP-ribose units from NAD⁺ to target proteins, thus blocking both mono- and poly-ADP-ribosylation events. This inhibition is reversible and concentration-dependent. In cellular assays, 3-Aminobenzamide achieves an IC50 of ~50 nM for PARP activity in CHO cells. At concentrations ≥1 μM, it yields >95% inhibition without detectable cellular toxicity (update: low toxicity, precise modulation). The compound's interference with PARP-mediated repair and transcriptional regulation is central to its research utility in oxidative stress, DNA damage, and viral-host interaction studies.

Evidence & Benchmarks

• 3-Aminobenzamide inhibits PARP activity in CHO cells with an IC50 of ~50 nM, producing >95% inhibition at ≥1 μM, without significant toxicity (product documentation).
• Pan-PARP inhibition enhances replication of macrodomain-mutant coronaviruses and reduces interferon responses in primary macrophages (Grunewald et al., 2019, https://doi.org/10.1371/journal.ppat.1007756).
• 3-Aminobenzamide improves endothelium-dependent, nitric oxide-mediated vasorelaxation after H₂O₂-induced oxidative stress (mechanistic extension).
• In diabetic db/db mice, the compound reduces albuminuria, mesangial expansion, and podocyte depletion, supporting diabetic nephropathy research (novel insights, translational applications).
• Solubility in water (≥23.45 mg/mL), ethanol (≥48.1 mg/mL), and DMSO (≥7.35 mg/mL) under ultrasonic assistance at room temperature ensures reliable assay integration (product documentation).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely applied in:

• PARP activity inhibition assays in cell lines and primary cells.
• Oxidative stress and DNA damage response research.
• Vascular function studies, especially nitric oxide-mediated relaxation.
• Diabetic nephropathy models, notably in db/db mice.
• Assessment of PARP-mediated viral restriction pathways (Grunewald et al., 2019).

For a detailed contrast with earlier perspectives, see this article, which focuses on solubility and practical assay design, whereas the current piece emphasizes cross-disease translational value and innate immunity context.

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not selective for individual PARP isoforms; it acts as a pan-inhibitor.
• It is for research use only and not for diagnostic, therapeutic, or medical applications.
• Long-term storage of solutions is discouraged due to potential compound degradation.
• Not suitable for in vivo therapeutic studies in humans; validated only in preclinical models.
• Reduced efficacy may occur in systems with high NAD⁺ concentrations due to competitive inhibition.

Workflow Integration & Parameters

For optimal results, prepare 3-Aminobenzamide solutions fresh prior to use. Dissolve in water (≥23.45 mg/mL), ethanol (≥48.1 mg/mL), or DMSO (≥7.35 mg/mL) using ultrasonic assistance to maximize solubility. Store solid compound at -20°C; avoid repeated freeze-thaw cycles. Use concentrations above 1 μM to achieve >95% PARP inhibition in cellular assays. Shipping is recommended with Blue Ice for small molecules. Always confirm compound identity and integrity with appropriate analytical methods prior to use (the A4161 kit).

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) is a robust, low-toxicity pan-PARP inhibitor, validated across multiple preclinical models for dissecting ADP-ribosylation, DNA repair, and innate immune processes. Its solubility, potency, and benchmarked efficacy support a wide range of research applications, from oxidative stress biology to diabetic nephropathy and host-virus interaction studies. Future directions include more selective PARP inhibitors and expanded utility in translational disease models. For up-to-date protocols and assay support, refer to the product page and recent peer-reviewed findings (Grunewald et al., 2019).